Related Experiment Video

Updated: Mar 21, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Hepatotoxicity of targeted therapy for cancer

Kirsty Wai-Chung Lee1, Stephen Lam Chan1,2

  • 1a Sir YK Pao Center for Cancer, Department of Clinical Oncology, State Key Laboratory in Oncology in South China , The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital , Shatin , Hong Kong.

Expert Opinion on Drug Metabolism & Toxicology
|May 18, 2016
PubMed
Abstract

Insights

Drug-induced liver injury from மருந்து-தொடர்புடைய புற்றுநோய் சிகிச்சைகள் (MTA) is common but manageable. Early intervention, like preventing viral hepatitis reactivation, is key to avoiding severe outcomes.

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Drug-induced liver injury (DILI) from மருந்து-தொடர்புடைய புற்றுநோய் சிகிச்சைகள் (MTA) can negatively impact cancer treatment outcomes.
  • A comprehensive understanding of MTA-associated hepatotoxicity is needed to guide clinical management.
  • This review addresses the current knowledge gap regarding MTA-induced liver injury.

Purpose of the Study:

  • To provide an organized overview of hepatotoxicity associated with மருந்து-தொடர்புடைய புற்றுநோய் சிகிச்சைகள் (MTA).
  • To summarize the mechanisms, clinical patterns, and management strategies for MTA-induced liver injury.

Main Methods:

  • A comprehensive literature review was conducted using PubMed.
  • Searches included case reports, relevant studies, FDA drug information, and the US National Library of Medicine LiverTox database.
  • All relevant மருந்து-தொடர்புடைய புற்றுநோய் சிகிச்சைகள் (MTA) were considered.

Main Results:

  • Hepatotoxicity associated with MTA is frequent but seldom fatal.
  • The liver injury pattern is predominantly idiosyncratic, meaning it is unpredictable and specific to individuals.
  • Pharmacogenomic approaches show promise for identifying patients at risk but require further prospective validation.

Conclusions:

  • MTA-associated hepatotoxicity is a significant clinical concern, necessitating proactive management.
  • Preventing viral hepatitis reactivation with antiviral medications is a crucial preventative measure.
  • Avoiding high-risk drug combinations can mitigate the incidence of DILI in cancer patients receiving MTA.
Keywords:
CYP polymorphismshepatitis reactivationhepatotoxicityimmunotherapymolecular targeted therapymonoclonal antibodiesmultikinase inhibitorspharmacogenomicstyrosine kinase inhibitors

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

625
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K